Cargando…
Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome
Background: Multiple trials have demonstrated the efficacy of fenofibrate for the management of dyslipidemia. Real-world evidence may provide important insights into the effectiveness and safety of fenofibrate in patients with metabolic syndrome and elevated triglyceride (TG) levels, but such eviden...
Autores principales: | Ezhov, Marat V., Arutyunov, Gregory P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594425/ https://www.ncbi.nlm.nih.gov/pubmed/37873784 http://dx.doi.org/10.3390/diseases11040140 |
Ejemplares similares
-
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia
por: Sun, Xiaomeng, et al.
Publicado: (2020) -
Hypertriglyceridemia‐induced pancreatitis after egg retrieval for in vitro fertilization and fenofibrate cessation
por: Shrimanker, Tushaar V., et al.
Publicado: (2022) -
Treatment of hypertriglyceridemia and HIV: fenofibrate-induced changes in the expression of chemokine genes in circulating leukocytes
por: Alonso-Villaverde, Carlos, et al.
Publicado: (2009) -
Fenofibrate Decreases Hepatic P-Glycoprotein in a Rat Model of Hereditary Hypertriglyceridemia
por: Poruba, Martin, et al.
Publicado: (2019) -
PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2016)